“This is the perfect technique to identify high-risk patients who would benefit from intensive therapies,” imaging specialist Gudrun Feuchtner, MD, told Cardiovascular Business.

Real-world patients were still associated with "excellent" outcomes, but it is important for cardiologists and patients alike to know as much as possible about the odds of survival following treatment. 

Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.

The goal is to measure changes in a patient’s IVC area and collapsibility, which can help anticipate when heart failure events might occur. This first-in-human study included data from the first 50 patients to receive the device. 

Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."